Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XytriX
- Development stage
- Phase 2
- Lead developer
- TricelX
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
XytriX is an allogeneic cell therapy product consisting of umbilical cord-derived mesenchymal stem cells (UC-MSCs), developed by TricelX for the treatment of knee osteoarthritis. The therapy is designed to leverage the innate regenerative and immunomodulatory properties of MSCs to reduce joint inflammation, alleviate pain, and potentially promote the repair of damaged articular cartilage. XytriX is administered via intra-articular injection and is currently being evaluated in Phase 1/2 clinical trials to establish its safety profile and therapeutic efficacy in patients with degenerative joint disease.
- Brand names
- XytriX
- Other names
- umbilical cord-derived mesenchymal stem cellUC-MSC
Beyond the preview
Go deeper on XytriX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XytriX.